Close Menu

NEW YORK – The US Food and Drug Administration today said it has cleared four enzyme immunoassay tests with new indications to diagnose Lyme disease.

The clearance marks the first time that the tests have been indicated to follow a new paradigm in which two enzyme immunoassay (EIA) tests can be conducted concurrently or sequentially, rather than running a Western Blot protein test after an initial EIA test, the agency said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.